Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for …
A Inoue, K Yoshida, S Morita, F Imamura… - Japanese journal of …, 2016 - academic.oup.com
Abstract Background The Japan Guidelines of Lung Cancer Therapy recommend epidermal
growth factor receptor-tyrosine kinase inhibitors as a first-line therapy for advanced/recurrent …
growth factor receptor-tyrosine kinase inhibitors as a first-line therapy for advanced/recurrent …
[HTML][HTML] Efficacy and safety of gefitinib as third-line treatment in NSCLC patients with activating EGFR mutations treated with first-line gefitinib followed by second-line …
Y Song, YL Wu, LJ Cao, JH Chen, ZY Ma… - American Journal of …, 2019 - journals.lww.com
Objective: There is no standard care for advanced non–small cell lung cancer (NSCLC)
patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study …
patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study …
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
F Cappuzzo, A Morabito, N Normanno, P Bidoli… - Lung Cancer, 2016 - Elsevier
Objectives Although patients with advanced non-small cell lung cancer (NSCLC) and an
activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR …
activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR …
[HTML][HTML] Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report
ZJ Han, N Luo, L Li, ZL Liu - Annals of Palliative Medicine, 2021 - apm.amegroups.org
Although tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR)
have a favorable and durable treatment response, almost all patients will eventually acquire …
have a favorable and durable treatment response, almost all patients will eventually acquire …
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient
G Metro, S Baglivo, A Siggillino, V Ludovini… - Clinical Drug …, 2018 - Springer
Osimertinib is the best treatment choice for patients with epidermal growth factor receptor
(EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) whose disease progresses …
(EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) whose disease progresses …
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer–A multicenter retrospective SEQUENCE …
GC Chang, CH Tseng, KH Hsu, CJ Yu, CT Yang… - Lung Cancer, 2017 - Elsevier
Background Acquired resistance occurs in most non-small cell lung cancer (NSCLC)
patients with epidermal growth factor receptor (EGFR) mutations experiencing a response to …
patients with epidermal growth factor receptor (EGFR) mutations experiencing a response to …
[HTML][HTML] Effectiveness and safety of EGFR-TKI rechallenge treatment in elderly patients with advanced non-Small-Cell lung cancer harboring drug-sensitive EGFR …
Y Yamada, H Imai, T Sugiyama, H Minemura… - Medicina, 2021 - mdpi.com
Background and Objectives: Epidermal growth factor receptor–tyrosine kinase inhibitors
(EGFR-TKIs) are effective first-line chemotherapeutic agents for patients with advanced non …
(EGFR-TKIs) are effective first-line chemotherapeutic agents for patients with advanced non …
[HTML][HTML] Role of sphingosine 1-phosphate in human pancreatic cancer cells proliferation and migration
YX Guo, YJ Ma, L Han, YJ Wang, JA Han… - International Journal of …, 2015 - ncbi.nlm.nih.gov
Deregulation of production or degradation of sphingosine 1-phosphate (S1P), a bioactive
lipid, involves in tumor progression, metastasis and chemoresistance. Since the tumor …
lipid, involves in tumor progression, metastasis and chemoresistance. Since the tumor …
Synthesis of Copolymers Polyethyleneimine‐co‐Polyphenylalanine as Gene and Drug Codelivery Carrier
C Liu, Z Guo, H Feng, L Lin, Y Cui… - Macromolecular …, 2021 - Wiley Online Library
In this study, a series of hyperbranched copolymers polyethyleneimine‐co‐
polyphenylalanine (PEI‐co‐PPhe) are synthesized by ring‐opening polymerization with …
polyphenylalanine (PEI‐co‐PPhe) are synthesized by ring‐opening polymerization with …
Efficacy of early combination of local radiotherapy and GM-CSF for advanced non-small cell lung cancer treated with icotinib
Y Qiu, X He, Z Li, Y Jiang, Y Jia - Irish Journal of Medical Science (1971-), 2020 - Springer
Background Lung cancer is a disease that severely endangers human health. Non-small
cell lung cancer (NSCLC) accounts for approximately 4/5 of lung cancers. Aims To …
cell lung cancer (NSCLC) accounts for approximately 4/5 of lung cancers. Aims To …